NCT07403721 2026-03-19
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Amgen
Phase 1 Recruiting
Clinical Trials
908 trialsNCT04443088 2026-03-18
KEYNOTE-E12
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1 Recruiting
NCT05719558 2026-03-18
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT04958239 2026-03-17
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT06150157 2026-03-16
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06540066 2026-03-16
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT06997029 2026-03-16
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Recruiting
NCT07030712 2026-03-16
MK-8294-001
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT05935098 2026-03-13
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT06178614 2026-03-13
A Study of JNJ-87890387 for Advanced Solid Tumors
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT05557045 2026-03-12
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
Jazz Pharmaceuticals
Phase 1 Recruiting
NCT07247110 2026-03-11
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT06555744 2026-03-06
A Study of ZW191 in Participants With Solid Tumors
Zymeworks BC Inc.
Phase 1 Recruiting
NCT07455617 2026-03-06
Study of ABO2102 in KRAS-Mutated Solid Tumors
Suzhou Abogen Biosciences Co., Ltd.
Phase 1 Not yet recruiting
NCT06713369 2026-03-04
AZD5305
AstraZeneca
Phase 1 Recruiting
NCT06803680 2026-03-04
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT03391778 2026-03-03
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
USWM, LLC (dba US WorldMeds)
Phase 1 Recruiting
NCT07046559 2026-03-03
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants
Eli Lilly and Company
Phase 1 Recruiting
NCT05382559 2026-03-02
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT06884618 2026-03-02
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
Hoffmann-La Roche
Phase 1 Recruiting
NCT06759649 2026-02-27
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
Compugen Ltd
Phase 1 Recruiting
NCT07438782 2026-02-27
First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Not yet recruiting
NCT06521554 2026-02-25
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Nuvalent Inc.
Phase 1 Recruiting
NCT07156136 2026-02-25
Study of IMC-P115C in Advanced PRAME-Positive Cancers
Immunocore Ltd
Phase 1 Recruiting
NCT00750841 2026-02-23
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
AstraZeneca
Phase 1 Active not recruiting
NCT06959706 2026-02-20
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Tagworks Pharmaceuticals BV
Phase 1 Recruiting
NCT05396833 2026-02-19
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
EMD Serono
Phase 1 Active not recruiting
NCT03964233 2026-02-18
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)
Boehringer Ingelheim
Phase 1 Completed
NCT06311578 2026-02-13
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
Johnson & Johnson Enterprise Innovation Inc.
Phase 1 Recruiting
NCT06607939 2026-02-10
OR2-01
Orionis Biosciences Inc
Phase 1 Recruiting
NCT07258836 2026-02-10
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
Eli Lilly and Company
Phase 1 Recruiting
NCT06717750 2026-02-02
A Study of CSCJC3456 in Patients With Advanced Malignant Tumors
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
Phase 1 Recruiting
NCT04170153 2026-01-30
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
EMD Serono
Phase 1 Active not recruiting
NCT02952248 2026-01-27
A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT07368127 2026-01-26
A Study of TPD3310 in Patients With Advanced Malignant Tumors
TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.
Phase 1 Not yet recruiting
NCT05914545 2026-01-22
A Study of FZ-AD004 in Patients With Advanced Solid Tumors
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT04471987 2026-01-14
DODEKA
Philogen S.p.A.
Phase 1 Recruiting
NCT07292038 2026-01-14
Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors
NucMito Pharmaceuticals Co. Ltd.
Phase 1 Recruiting
NCT06235437 2026-01-07
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141
Ascendo Biotechnology Co., Ltd.
Phase 1 Recruiting
NCT06952010 2025-12-26
A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Exelixis
Phase 1 Recruiting
NCT05270213 2025-12-19
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Riboscience, LLC.
Phase 1 Recruiting
NCT02275910 2025-12-16
Phase 1 Study of E7090 in Subjects With Solid Tumor
Eisai Inc.
Phase 1 Completed
NCT05165433 2025-12-16
FORTIFY
Akamis Bio
Phase 1 Completed
NCT06108050 2025-12-16
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
Jazz Pharmaceuticals
Phase 1 Recruiting
NCT04898543 2025-12-11
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
ImmunityBio, Inc.
Phase 1 Active not recruiting
NCT06724042 2025-12-10
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited
Phase 1 Not yet recruiting
NCT06299839 2025-12-03
PAS-004 in Patients With Advanced Solid Tumors
Pasithea Therapeutics Corp.
Phase 1 Recruiting
NCT03449381 2025-11-26
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Completed
NCT05586321 2025-11-24
Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors
Genmab
Phase 1 Completed
NCT05629689 2025-11-17
A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET Scans in Patients With Solid Tumour Malignancies
GE Healthcare
Phase 1 Recruiting